Antares Pharma (ATRS) Tops Q4 EPS by 1c

Antares Pharma (NASDAQ: ATRS) reported Q4 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $14 million versus the consensus estimate of $15.65 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Oxford Industries (OXM) Tops Q1 EPS by 12c; Offers Outlook
• Adobe Systems (ADBE) Tops Q2 EPS by 14c, Offers Guidance